EDX MEDICAL GROUP PLC

13277385
Active Cambridge

Activities of venture and development capital companies

21 employees website.com
Life sciences and medical technology Activities of venture and development capital companies
E

EDX MEDICAL GROUP PLC

13277385

Activities of venture and development capital companies

Founded 19 Mar 2021 Active Cambridge, England 21 employees website.com
Life sciences and medical technology Activities of venture and development capital companies

Previous Company Names

TECC CAPITAL PLC 19 Mar 2021 — 11 Nov 2022
Accounts Submitted 17 Sept 2025 Next due 30 Sept 2026 2 months remaining
Confirmation Submitted 9 Mar 2026 Next due 16 Mar 2027 8 months remaining
Net assets £3M £710K 2024 year on year
Total assets £4M £2M 2024 year on year
Total Liabilities £964K £1M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

211 Cambridge Science Park Milton Road Cambridge Cambs CB4 0WA England

Website

www.example.com

Full company profile for EDX MEDICAL GROUP PLC (13277385), an active life sciences and medical technology company based in Cambridge, England. Incorporated 19 Mar 2021. Activities of venture and development capital companies. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Apr → 31 Mar 2025
Type group
Next accounts 31 Mar 2026
Due by 30 Sept 2026 2 months remaining

Balance Sheet & P&L (2021–2024)

Cash in Bank

£2.40M

Decreased by £1.67M (-41%)

Net Assets

£2.77M

Decreased by £710.00k (-20%)

Total Liabilities

£964.00k

Decreased by £1.15M (-54%)

Turnover

£322.00k

Increased by £94.00k (+41%)

Employees

21

Increased by 2 (+11%)

Debt Ratio

26%

Decreased by 12 (-32%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Mar Year End
2024
31 Mar Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 9

Investors (18)

Investor NameInvestor SinceParticipating Rounds
Investor 6Jul 2022Bridge/Convertible
Investor 7Apr 2023Seed
Investor 8Apr 2023Seed

Share Capital

Share Capital

Share allotments and capital structure

20 Allotments 409,267,111 Shares £54416683.39m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
9 Jun 2026150,000£15k£0.1
3 Mar 2026250,000£25k£0.1
20 Feb 202624,999,999£3.50m£0.14
23 Oct 202514,285,713£2.00m£0.14
3 Jun 2025150,000£15k£0.1

Officers

Officers

1 active 2 resigned
Status
Jones, Trevor Mervyn, Dr.DirectorBritishEngland8314 Nov 2022Active

Shareholders

Shareholders (5)

Bridgemere Securities Limited
11.6%
Christopher Akers
11.1%

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Professor Christopher Thomas Evans

British

Active
Notified 21 Nov 2022
Residence England
DOB November 1957
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent

John Edward Taylor

Ceased 3 Jun 2021

Ceased

Donald John Stewart

Ceased 3 Jun 2021

Ceased

Group Structure

Group Structure

EDX MEDICAL GROUP PLC Current Company
EDX MEDICAL LTD united kingdom
HUTANO DIAGNOSTICS LTD united kingdom

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
17 Jun 2026CapitalAllotment of shares (GBP 4,119,945.83) on 9 Jun 2026
13 Mar 2026Persons With Significant ControlChange to Professor Christopher Thomas Evans as a person with significant control on 12 Mar 2026
9 Mar 2026Confirmation StatementConfirmation statement made on 2 Mar 2026 with no updates
4 Mar 2026CapitalAllotment of shares (GBP 4,118,445.83) on 3 Mar 2026
23 Feb 2026CapitalAllotment of shares (GBP 4,115,945.83) on 20 Feb 2026
17 Jun 2026 Capital

Allotment of shares (GBP 4,119,945.83) on 9 Jun 2026

13 Mar 2026 Persons With Significant Control

Change to Professor Christopher Thomas Evans as a person with significant control on 12 Mar 2026

9 Mar 2026 Confirmation Statement

Confirmation statement made on 2 Mar 2026 with no updates

4 Mar 2026 Capital

Allotment of shares (GBP 4,118,445.83) on 3 Mar 2026

23 Feb 2026 Capital

Allotment of shares (GBP 4,115,945.83) on 20 Feb 2026

Recent Activity

Latest Activity

Allotment of shares (GBP 4,119,945.83) on 9 Jun 2026

2 weeks ago on 17 Jun 2026

Change to Professor Christopher Thomas Evans as a person with significant control on 12 Mar 2026

3 months ago on 13 Mar 2026

Confirmation statement made on 2 Mar 2026 with no updates

3 months ago on 9 Mar 2026

Allotment of shares (GBP 4,118,445.83) on 3 Mar 2026

4 months ago on 4 Mar 2026

Allotment of shares (GBP 4,115,945.83) on 20 Feb 2026

4 months ago on 23 Feb 2026